Role of biologics in asthma
Patients with severe uncontrolled asthma have disproportionally high morbidity and
healthcare utilization as compared with their peers with well-controlled disease. Although …
healthcare utilization as compared with their peers with well-controlled disease. Although …
Anti‐IL‐5 therapies for asthma
Antecedentes Esta la segunda actualización de una revisión publicada anteriormente en la
Biblioteca Cochrane (2015, primera actualización en 2017). La interleucina 5 (IL‐5) es la …
Biblioteca Cochrane (2015, primera actualización en 2017). La interleucina 5 (IL‐5) es la …
Asthma phenotypes and IgE responses
A Froidure, J Mouthuy, SR Durham… - European …, 2015 - publications.ersnet.org
The discovery of IgE represented a major breakthrough in allergy and asthma research,
whereas the clinical interest given to IgE in asthma has been blurred until the arrival of anti …
whereas the clinical interest given to IgE in asthma has been blurred until the arrival of anti …
Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?
A Matucci, A Vultaggio, E Maggi, I Kasujee - Respiratory research, 2018 - Springer
Bronchial asthma (BA) is a chronic inflammatory disease with a marked heterogeneity in
pathophysiology and etiology. The heterogeneity of BA may be related to the inducing …
pathophysiology and etiology. The heterogeneity of BA may be related to the inducing …
Biologics in asthma: a molecular perspective to precision medicine
Recent developments in therapeutic strategies have provided alternatives to corticosteroids
as the cornerstone treatment for managing airway inflammation in asthma. The past two …
as the cornerstone treatment for managing airway inflammation in asthma. The past two …
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
C Pelaia, C Calabrese, R Terracciano… - Therapeutic …, 2018 - journals.sagepub.com
Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …
[HTML][HTML] Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms
Background Asthma is a chronic inflammatory disease involving diverse cells and mediators
whose interconnectivity and relationships to asthma severity are unclear. Objective We …
whose interconnectivity and relationships to asthma severity are unclear. Objective We …
Omalizumab in asthma: an update on recent developments
IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …
Human mast cells and basophils—How are they similar how are they different?
Mast cells and basophils are key contributors to allergies and other inflammatory diseases
since they are the most prominent source of histamine as well as numerous additional …
since they are the most prominent source of histamine as well as numerous additional …
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison
Aims To compare the efficacy of tezepelumab with other approved biologics via indirect
treatment comparisons (ITCs) in patients aged≥ 12 years with severe uncontrolled asthma …
treatment comparisons (ITCs) in patients aged≥ 12 years with severe uncontrolled asthma …